Exploiting epigenetic targets to overcome taxane resistance in prostate cancerBuse Cevatemre, Ceyda Açılan, İpek Bulut et al.|Cell Death and Disease|2024Cited by 20
Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survivalEzgi Ozyerli‐Goknar, Tugba Bagcı-Önder, Hamzah Syed et al.|Cell Communication and Signaling|2023Cited by 12
Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancerOzlem Yedier-Bayram, Tugba Bagcı-Önder, Ahmet Cingöz et al.|Experimental & Molecular Medicine|2025Cited by 4
Epidrug screening identifies type I PRMT inhibitors as modulators of lysosomal exocytosis and drug sensitivity in cancersBaris Sergi, Neslihan Yuksel-Catal, Selahattin Can Özcan et al.|Cell Death and Disease|2025Cited by 3
Butyrylcholinesterase (BChE) downregulation in taxane resistance: implications for prostate cancerBuse Cevatemre, Ceyda Açılan, İpek Bulut et al.|TURKISH JOURNAL OF BIOLOGY|2025Cited by 1